According to the World Health Organization, cancer diagnoses remain a leading cause of death. However, scientific and medical communities have improved clinical outcomes for many people, transforming ...

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences. Minimal residual disease (MRD) ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

The CEPHEUS trial is a trial for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplantation, or in whom a transplant was deferred. And 395 patients were randomized ...

MILAN — The landscape of hematologic malignancies is shifting rapidly, in part due to the evolving significance of measurable (formerly "minimal") residual disease (MRD). Once confined to the realm of ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...

Over the last decade, molecular residual disease (or minimal residual disease; MRD) has emerged as a powerful dynamic biomarker in oncology. Defined as a very small number of tumor cells remaining ...

Measurable residual disease (MRD) is a critical diagnostic tool that predicts disease progression and is increasingly used as an important end point to monitor disease status and evaluate novel ...

Haystack MRD test detects minimal residual disease in stage 2 colorectal cancer patients post-surgery, using circulating tumor DNA (ctDNA) for less invasive monitoring. The FDA's breakthrough device ...

RIO DE JANEIRO — A quadruplet induction regimen of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in the treatment of newly diagnosed multiple myeloma (MM) shows a notably high ...